Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease
Author:
Publisher
Baishideng Publishing Group Inc.
Subject
Gastroenterology,General Medicine
Reference90 articles.
1. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
2. Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends
3. Current global trends in the incidence of pediatric-onset inflammatory bowel disease
4. Inflammatory Bowel Disease in Children and Adolescents
5. US Department of Health & Human Services. Drugs @ FDA-label and approval history. In: Food and Drug Administration. [cited 2022 December 28]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphis/
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Adalimumab as treatment for neurosarcoidosis: A case series;Journal of the Neurological Sciences;2024-05
2. Are Radiomic Spleen Features Useful for Assessing the Response to Infliximab in Patients With Crohn's Disease? A Multicenter Study;Clinical and Translational Gastroenterology;2024-02-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3